Cochrane · systematic review · CD010774
Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma
Peinemann, F, Kahangire, DA, van Dalen, EC, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
Childhood CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
6
No studies
1
Included studies
NR
No studies 1 · 14.3%Ungraded 0 · 0%Very low 0 · 0%Low 6 · 85.7%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Rapid COJEC compared to standard induction therapies for high‐risk neuroblastoma
Population: patients with high‐risk neuroblastoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Complete response Rapid COJEC vs standard induction therapies | RR 0.99 [0.71, 1.38] | 1 study · 170 participants | Low Downgraded: risk of bias |
Early toxicities (during preoperative chemotherapy): febrile neutropenia (2 or more episodes), proven fungal infections, septicemia (1 or more episodes), gastrointestinal toxicity (grade 3 or 4), renal toxicity (glomerular filtration rate < 80 ml/... Rapid COJEC vs standard induction therapies | no estimate extracted | 1 study · 248 participants | Low Downgraded: risk of bias |
Treatment‐related mortality Rapid COJEC vs standard induction therapies | RR 1.21 [0.33, 4.39] | 1 study · 234 participants | Low Downgraded: risk of bias |
Overall survival Rapid COJEC vs standard induction therapies | HR 0.83 [0.63, 1.1] | 1 study · 262 participants | Low Downgraded: risk of bias, imprecision |
Progression‐free survival ‐ not reported Rapid COJEC vs standard induction therapies | no estimate extracted | NR | No studies |
Event‐free survival Rapid COJEC vs standard induction therapies | HR 0.86 [0.65, 1.13] | 1 study · 262 participants | Low Downgraded: risk of bias, imprecision |
Late non‐hematological toxicities: any complication, renal toxicity (Glomerular Filtration Rate < 80 ml/min per body surface area of 1.73 m2), ototoxicity (Brock grade 1 to 4), endocrine complications (see table of included studies for included di... Rapid COJEC vs standard induction therapies | no estimate extracted | 1 study · 57 participants | Low Downgraded: risk of bias |